A Phase 1 Study of E7080 in Subjects With Solid Tumor

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221345

Enrollment

Registered

2011-01-05

Start date

2011-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumor

Interventions

investigational material(s) Generic name etc : E7080 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Subjects with histologically and/or cytologically diagnosis of solid tumor 2)Subjects with solid tumor which is resistant to standard anti-tumor therapies, or which no appropriate treatment is available 3)Subjects whose toxicity of previous treatment has recovered to Grade 1 or lower toxicity (except for alopecia) 4)Subjects who completed previous anti-tumor therapy before at least 4 weeks 5)Subjects who are 20 years or older 6)Subjects with 0 to 1 of PS 7)Subjects agree to be hospitalized for DLT observation. 8)Subjects with adequate organ functions 9)Males and females of childbearing potential must agree to use appropriate contraception from the agreement to 30 days after study drug administration. 10)Agree to participate in this study in writing based on voluntary will

Exclusion criteria

Exclusion criteria: 1)Subjects with brain metastasis accompanying clinical symptoms or requiring treatment 2)Subjects with the severe complication or disease history 3)Subjects unable to take oral medication. 4)Subjects being treated with drugs that strongly inhibit or induce CYP3A4 and that may be possibly used during this study. 5)Scheduled for surgery during the projected course of the study. 6)Positive for human immunodeficiency virus (HIV antibody) test or positive for hepatitis B surface (HBs antigen) or hepatitis C (HCV antibody) by serum test. 7)Subjects who in the view of the investigator are not able to comply with this protocol because of psychiatric or physical diseases including alcoholism or drug addict 8)Pregnant or nursing subjects 9)Subjects who are participating in another clinical trial.

Design outcomes

Primary

Measure	Time frame
To investigate the number of subjects with adverse events.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026